Helix BioPharma Corp.

Equities

HBP

CA4229101098

Biotechnology & Medical Research

Market Closed - Toronto S.E. 09:30:00 2024-03-18 am EDT 5-day change 1st Jan Change
0.18 CAD -5.26% Intraday chart for Helix BioPharma Corp. -2.70% -14.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Helix BioPharma Corp. Appoints Praveen Varshney as Corporate Secretary CI
Helix BioPharma Corp. Appoints Praveen Varshney as Chief Financial Officer CI
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment DJ
Helix BioPharma Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023 CI
North American Morning Briefing : Traders Eye -2- DJ
Helix BioPharma Corp. Reports Earnings Results for the Full Year Ended July 31, 2023 CI
Helix BioPharma Corp. announced that it has received CAD 2.998 million in funding CI
Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics CI
Helix Biopharma Corp. Announces Board Changes CI
Helix BioPharma Corp. Announces Executive Changes CI
Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in funding CI
Helix BioPharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023 CI
North American Morning Briefing : Futures Rise -2- DJ
Helix BioPharma Corp. Reports Earnings Results for the First Quarter Ended October 31, 2022 CI
North American Morning Briefing : Investors Wary -2- DJ
Helix BioPharma Corp. Announces Board Changes CI
Helix BioPharma Corp. Announces CEO Changes CI
Helix BioPharma Corp. Reports Earnings Results for the Full Year Ended July 31, 2022 CI
Helix BioPharma Corp. announced that it has received CAD 4.62902 million in funding CI
Helix BioPharma Corp. Auditor Raises 'Going Concern' Doubt CI
Helix BioPharma Corp. Appoints Frank Gary Renshaw as Chief Medical Officer CI
Helix BioPharma Corp. announced that it expects to receive CAD 4.62902 million in funding CI
Helix BioPharma Corp. Appoints Gabrielle M Siegers as Head of Research Development Based Out of its Lab in Edmonton CI
Helix BioPharma Corp. Enters into Two-Year Scientific Collaboration Agreement with University Hospital Tuebingen CI
Helix BioPharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2022 CI
Chart Helix BioPharma Corp.
More charts
Helix BioPharma Corp. is a Canada-based a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47. DOS47 is an oncology platform technology that offers a potentially approach to the debilitation and destruction of cancer cells. DOS47 is designed to stimulate an increase in the Potential of Hydrogen (pH) of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra cellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody and is under clinical study for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. V-DOS47 targets the vascular endothelial growth factor two recept
More about the company

Annual profits - Rate of surprise